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Microparticles (MPs) are small vesicles shed from the cytoplasmic membrane of healthy, activated, or apoptotic cells. MPs are
very heterogeneous in size (100–1,000 nm), and they harbor proteins and surface antigens specific to cells they originate from.
Virtually, all cells can shed MPs, and therefore, they can be found in all body fluids, but also entrapped in tissues. Of interest
and because of their easy detection using a variety of techniques, circulating MPs were recognized as biomarkers for cell
activation. MPs were also found to mediate critical actions in intercellular communication and transmitting biological
messages by acting as paracrine vehicles. High plasma numbers of MPs were reported in many cardiovascular and metabolic
disturbances that are closely associated with insulin resistance and low-grade inflammation and have been linked to adverse
actions on cardiovascular function. This review highlights the involvement of MPs in cardiovascular complications associated
with diabetes and discusses the molecular mechanisms that underpin the pathophysiological role of MPs in the onset and
progression of cellular injury in diabetes.
1. Introduction
Microparticles (MPs) are membrane-shed vesicles, ranging
in size between 100nm and 1,000 nm, that are released from
the cytoplasmic membrane of activated and/or apoptotic
cells. For many decades, MPs were considered inert cell
debris or platelet dust derived from platelets which are rich
in phospholipids and endowed of procoagulant capacity
[1]. Later, the development of methods of genetic and pro-
tein profiling showed that MPs could transport cargo con-
tent including secretable and nonsecretable biological
molecules such as active lipids and nucleic acids, such as
coding (mRNA) and noncoding (e.g., microRNA and long
noncoding RNA) RNA and DNA, in addition to membrane
and cytosolic proteins to target cells [2] and are therefore
recognized today as true vectors of intercellular communica-
tion and mediators of a variety of biological messages.
MPs are involved in the regulation of molecular processes
within the emitting cell itself or other distant cells. Cells may
export into the extracellular environment certain subcellular
organelles and macromolecules or genetic material (e.g.,
mRNA or microRNA) because of their role in controlling
certain cell functions inside the cell or because they are
directly involved in the control of the process of MP shedding
and release. The elimination of these molecules entrapped
within MPs may alter the properties of the parent cells such
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as the modulation of intracellular levels of some specific
microRNAs or regulatory signaling molecules and second
messengers [3].
The release of MPs to the extracellular environment will
bring them in contact with neighboring cells, or if they reach
systemic circulation, MPs can interact with cells of different
types at remote sites within the body. MPs can interact with
target cells in multiple ways ranging from a ligand-receptor
type of interaction to their surface antigens, through mem-
brane fusion with target cell or internalization which allows
for dumping of MP cargo content inside the target cell [3].
Target cells, if they did not degrade MP content or eliminate
it outside of the cell inside new vesicles, may respond to sig-
naling molecules brought by MPs which eventually can alter
cellular functions and responses within the recipient cell [4].
The shedding of MPs from cells is a natural mechanism,
and virtually, any cell in the body is capable of releasing MPs
into the extracellular environment. However, the cellular
mechanisms governing the shedding of MPs are not fully elu-
cidated. Many studies have reported that MPs are present in
various body fluids and solid tissues from both healthy
humans and animal models; however, the number of these
MPs was found to be increased in pathological states and
may constitute therefore good biomarkers for the prognosis
and diagnosis of multiple pathologies [5]. In relation to car-
diovascular diseases and complications, MPs from different
cellular origins were reported to be increased in the blood
of patients including those derived from circulating cells such
as platelets, leukocytes, red cells, endothelial cells, and
smooth muscle cells; however, much of circulating MPs
detected were from platelet origin [5].
The current review article focuses on the involvement of
MPs in diabetes-induced complications. Furthermore, it dis-
cusses the molecular mechanisms that underpin the patho-
physiological role of MPs in the induction and progression
of cellular injury associated with diabetes.
2. Differences between MPs and Other
Extracellular Vesicles and
Mechanisms of Formation
MPs are not the only vesicles of cell origin that can be found
in body fluids; other types of extracellular vesicles are also
documented such as exosomes and apoptotic bodies. How-
ever, the mechanisms controlling the liberation of these dif-
ferent vesicles are not the same (Table 1).
2.1. Formation and Release of MPs.MPs are directly released
from the cytoplasmic membrane of cells. They are very
heterogeneous in size (100–1,000 nm) and content but con-
tain cytosolic cargo. The mechanisms of membrane remodel-
ing implicated in the formation of MPs are not completely
understood; however, much evidence indicates that the
release of MPs happens after the activation of cells either
chemically or physically or when cells undergo apoptosis.
The number of MPs shed, and their qualitative content was
reported to vary according to the types of stimuli at the origin
of MP shedding [6, 7].
The release of MPs from cell membrane formation
requires membrane remodeling following cell stimulation
and the activation of cascades of intracellular signals. Bleb
formation from plasma membranes, an indicator of MPs
shedding, was shown to take place when an influx of calcium
inside the cell occurs following cell activation. Following this
intracellular calcium surge, cell blebbing is allowed via the
activity of cysteine protease, μ calpain, which leads to the
breakdown of cytoskeleton constituents, talin, and α-actinin
[8]. In platelets, it has been reported that μ calpain inhibition
prevented MP shedding and that μ calpain activation was
mediated through an elevation of cyclic AMP (cAMP) levels
and the subsequent activation of protein kinase A (PKA) [9].
It is in general well agreed that MPs are shed when the
asymmetry of membrane phospholipid distribution between
the inner and outer layers is disrupted or lost. In a basal
condition, the negatively charged aminophospholipid, phos-
phatidylserine (PS), is essentially located in the inner leaflet
of the cytoplasmic membrane. However, during cell activa-
tion or apoptosis, a prominent change in membrane asym-
metry is the externalization of PS to the outer leaflet. The
externalization of PS is an early indicator of the process
of MP shedding. Because of its negative charge, PS exter-
nalization creates an excess of negative charges at the cell
surface and imbalances the molecular masses of the two
leaflets, which in turn could contribute to membrane desta-
bilization and the formation of blebs. Maintaining mem-
brane phospholipid asymmetry is pivotal for the proper
function of cell membrane.
Loss or disruption of membrane asymmetry is tightly
linked to cell activation and is associated with various dis-
ease states. Phospholipid asymmetry is maintained by the
selective synthesis of specific phospholipids on each side of
a cell membrane. Several proteins are involved in maintain-
ing lipid asymmetry either by persevering or by disrupting
the gradient of lipid distribution between the inner and out
leaflets. There are three main classes of these protein: (i) flip-
pase, directed toward the cytosol and ATP-dependent trans-
porters; (ii) floppases, directed toward the extracellular
environment and ATP-dependent transporters; and (iii)
scramblases, bidirectional and ATP-independent trans-
porters. Scramblases allow for a random distribution of
lipids between the membrane bilayers. The flippases are very
selective for PS, and their action is responsible for maintain-
ing this phospholipid mainly sequestered at the inner leaflet
of the cell membrane [10]. A sustained increase in intracellu-
lar calcium following cell activation or apoptosis inhibits flip-
pases and therefore contributes to surface exposure of PS
because of the overwhelming action of floppases [11, 12].
The disruption of cell membrane asymmetry and changes in
masses of the two leaflets in addition to the calcium-induced
proteolytic degradation of cytoskeleton caused by the activa-
tion of μ calpains lead to the formation of membrane blebs
and MP release [12].
MPs exposing PS at their surface provide sites for the
assembly of coagulation factors and participate thus to the
process of hemostasis. Platelets have a very high rate of
scrambling of membrane lipids and thus can rapidly generate
MPs exposing PS which contributes in preventing bleeding;
2 Oxidative Medicine and Cellular Longevity
however, an excessive shedding of MPs may cause throm-
botic complications [12]. Sinauridze et al. [13] reported that
one single platelet-derived MP had nearly the same procoa-
gulant activity as one activated platelet despite the surface
area was 2 orders of magnitude smaller suggesting that
platelet-derived MPs have a procoagulant surface that is 50-
to 100-fold more potent than activated platelets [13].
However, not all MPs appear to express PS at their sur-
face. Connor et al. [14] demonstrated that in nonstimulated
plasma that is poor in platelets, about 80% of platelet-shed
MPs were unable to interact with annexin V. They also
reported that the fraction of MPs that successfully interacted
with annexin V was dependent upon the nature of the stim-
ulus used. Naturally stimulating molecules such as collagen
produced less MPs positively labeled with annexin V as com-
pared to nonphysiological agonists such as calcium iono-
phore [14]. Furthermore, in our own hands, we observed
that MPs exposing PS (positive for annexin V) represented,
at the most, 50% of total MPs detected in the plasma from
patients with metabolic syndrome, septic shock, and sleep
apnea for instance [15–18]. Therefore, it is reasonable to sug-
gest that we still lack some understating about the signifi-
cance of shedding of these MPs that do not expose PS at
their surface and that other cellular mechanisms are involved
in their biogenesis, which warrants further research.
Other molecular events were identified to bridge the link
between the sustained increase in intracellular calcium fol-
lowing activation and externalization of PS andMP shedding
and release from cell membranes. It has been proposed that
externalization of PS is related to the entry of calcium
through membrane calcium channels, which follows deple-
tion of intracellular calcium stores; this phenomenon is
known as capacitative or store-operated calcium entry
(SOCE), and it has been shown that this event together with
the externalization of PS is partly regulated by actin
cytoskeleton [19]. The small GTPase Rho A, which interacts
with the extracellular signal-regulated kinase (ERK) pathway,
was found to regulate SOCE and the surface externalization
of PS through the rearrangement of actin cytoskeleton [20].
The phosphorylation of myosin light chain (MLC) causes
actin/myosin-mediated contractile tension, leading thus to
an increase in the pressure on the cytoplasm structure, which
eventually causes membrane bleb formation. The phosphor-
ylation of MLC was shown to be mediated, during apoptosis,
by the serine/threonine kinase Rho-associated protein
kinase- (ROCK-) I, one of the effectors downstream of the
small GTPase Rho. ROCK-I was found be activated in apo-
ptosis by proteolytic cleavage by caspase 3, and the active
kinase can then simultaneously phosphorylate and hence
activate MLC, then phosphorylate and thus inactivate MLC
phosphatase [12, 21, 22].
2.2. Formation and Release of Exosomes and Apoptotic
Bodies. Another example of extracellular vesicles found in
body fluids including systemic circulation is exosomes that
have a size ranging between 40 and 150nm [23–25]. Exo-
somes are released upon the fusion of multivesicular bodies
with cell membrane. Their content is very distinct from
MPs owing to their specific mode of formation. The forma-
tion of exosomes takes place within endosomes by introver-
sion of the delineating membranes causing the generation
of multivesicular bodies. Subsequently, these multivesicular
bodies merge with the cytoplasmic membrane releasing thus
exosomes outside of the cell [26].
The detection of exosomes is supported by both struc-
tural and molecular features. Because of their small size, exo-
somes can be collected following high-speed centrifugations
above 100,000 g. Exhaustive proteomic profiling of MPs
and exosomes derived from many cell types found that exo-
somes are exclusively enriched in some stereotypic protein
Table 1: Major differences between extracellular vesicles found in body fluids.
Apoptotic bodies Microparticles (MPs) Exosomes
Size of vesicles >1,000 nm 100 nm–1,000 nm <100 nm
Isolation
method
Low to moderate speed centrifugation
(<10,000 g) High-speed centrifugation (<21,000 g) Ultracentrifugations (>100,000 g)
Origin Cytoplasmic membrane Cytoplasmic membrane Endocytic lysosomal system
Mechanism of
shedding and
release
Cytoplasmic membrane cytoskeletal
rearrangement and loss of membrane
asymmetry and release of bodies
Cytoplasmic membrane cytoskeletal
rearrangement and loss of membrane
asymmetry and release of bodies
facilitated by calcium-dependent
degradation of cytoskeleton
Fusion of multivesicular bodies
(MVBs) with cytosolic membrane
and exocytosis to extracellular
environment
Most used
techniques for
detection and
quantification
Flow cytometry, immunofluorescence,
electron and atomic force microscopies,
light scattering technique, western
blotting, ELISA-based tests
Flow cytometry, immunofluorescence,
electron and atomic force microscopy,
light scattering technique, western
blotting, ELISA-based tests
Immunofluorescence, electron
microscopy, light scattering
technique, western blotting,
ELISA-based tests
Commonly
used markers
for detection
High levels of phosphatidylserine
Selectins, integrins, cell-specific surface
antigens (cluster of differentiation or
CD), phosphatidylserine
Tetraspanins (e.g., TSPAN29 and
TSPAN30), ESCRT components,
PDCD6IP, TSG101, flotillin,
MFGE8, lactadherin, LAMP1
Abbreviations: ESCRT, endosomal sorting complexes required for transport; LAMP1, lysosomal-associated membrane protein 1; MFGE8, milk fat globule-EGF
factor 8 protein; PDCD6IP, programmed cell death 6-interacting protein; TSG101, tumor susceptibility gene 101; TSPAN, tetraspanins.
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markers such as TSG101, cell death 6-interacting protein
(PDCD6IP), and tetraspanin 30 (CD63) while MPs do not
express these markers [27, 28].
Cells undergoing apoptosis can release larger vesicles
referred to as apoptotic bodies with sizes larger than
1,000 nm which are generated by the uncoordinated blebbing
of cytoplasmic membrane and can carry nuclear parts and
proteins. Under certain conditions, the number of apoptotic
bodies exceeds those of exosomes and MPs and their content
can differ between various body fluids [2].
These various types of membrane vesicles found in the
extracellular environments can be discriminated according
to multiple structural and physical properties. Sequential
rounds of high-speed centrifugations are the most effective
method to isolate cells, debris, apoptotic bodies, MPs, and
exosomes. MPs are collected from the supernatant resulting
from the elimination of cell debris by additional cycles of
centrifugation with a speed ranging between 10,000 and
21,000 g whereas the isolation of exosomes requires ultra-
centrifugation speeds above 100,000 g (Table 1). It is possi-
ble to discriminate between apoptotic bodies, MPs, and
exosomes by electron microscopy or flow cytometry,
although owing to their detection limits, flow cytometers
are believed not be optimal for the detection of exosomes
because of their small size.
3. Composition of MPs
3.1. Protein Content of MPs.MP content mirrors the remod-
eling and rearrangement of the cytoplasmic membrane of the
parent cell that is shedding them. Several studies including
those involving molecular profiling methods such as proteo-
mic techniques revealed that protein cargo content of MPs
does not only depend on the nature of parent cells but also
depend on the stimulating conditions at the origin of MP
generation [29, 30]. It has been reported previously for exam-
ple that MPs engineered in vitro from T lymphocytes using
different stimuli carry key differences in their cargo protein
content. It was found that MPs, generated from T lympho-
cytes activated with phytohemagglutinin (PHA) for 72 hours
and then induced in apoptosis with additional stimulation
for further 24 hours with phorbol-12-myristate-13 (PMA)
and actinomycin D, expressed the morphogen sonic hedge-
hog (Shh) [7]; however, apoptotic T lymphocytes (stimulated
with actinomycin D only for 24 hours) generated MPs
which were deficient in Shh [6]. It has been observed that
only the treatments of T lymphocytes with PHA, PMA,
and actinomycin D or with PHA/actinomycin D were able
to generate MPs carrying Shh [31]. However, the mecha-
nisms behind this differential expression in protein content
are not yet clear.
The differential expression of Shh translated into differ-
ences in the biological messages carried out by MPs gener-
ated from T lymphocytes. T lymphocyte MPs harboring
Shh induced nitric oxide (NO) release from endothelial
cells and reversed endothelial dysfunction causing ische-
mia/reperfusion of the left descending anterior coronary
artery in mice [7] and improved endothelial dysfunction
in a mouse model of angiotensin II-induced hypertension
[32]. However, T lymphocyte MPs deficient for Shh reduced
NO bioavailability in endothelial cells and caused endothe-
lial dysfunction in mouse aortas [6]. MPs carrying Shh
were found to activate the Shh signaling pathway in target
cells [33].
Proteomic analysis of MPs derived from control and
β-cells of islets of Langerhans stimulated with cytokines for
24 hours showed that several proteins were differentially
expressed by the two populations of MPs. Multiple members
of the tumor necrosis factor (TNF) transduction pathway
were upregulated in MPs obtained from cells stimulated
with cytokines, such as the TNF receptor superfamily
member 1A, TNFα-induced protein 3, and TNF-interacting
kinase receptor-interacting serine-threonine kinase 1 [34].
Xu et al. [35] performed a proteomic analysis of circulat-
ing MPs from newly diagnosed type-2 diabetics and healthy
volunteers. The authors found 46 proteins that were differen-
tially expressed byMPs between diabetic patients and healthy
volunteers. Of these proteins, 20 proteins were increased in
diabetic MPs and 17 others were only found in MPs from
healthy subjects. Of interest, it was found that diabetic MPs
expressed significantly higher levels of Ras-related protein
Rap-1b (RAP1B), CD9, and integrin alpha-IIb (ITGA2B,
CD41) [35]. All these molecules play a role in hemostasis
and platelet activation and aggregation; however, the increase
in CD41 expression is not surprising because this is an essen-
tial platelet glycoprotein and that platelet-derived MPs repre-
sent over 80% of all circulating MPs [5]. Xu and colleagues
[35] also reported that the expression of S100A8 and
S100A9 was significantly elevated in MPs from diabetic
patients [35]. A previous proteomic study also found that
S100A8 and S100A9 were highly increased in chronic dia-
betic foot exudates compared to exudates from split-skin
donor sites of burn victims who are otherwise healthy [36].
Both S100A8 and S100A9 are inflammatory mediators,
which can bind to advanced glycation end-products (AGEs)
receptors and toll-like receptors (TLRs) to let go inflamma-
tory cytokines [37]. The genetic deletion of S1009A in
atherosclerosis-prone Apo E-deficient mice reduced athero-
genesis [38]. These findings support reports indicating that
MPs from diabetic patients, especially those from platelets,
have a stronger procoagulant potential which contributes to
the hypercoagulability in these patients and strengthens the
evidence for a potential role of MPs in vascular pathogenesis
in diabetes.
Because they originate from the cell membrane, MPs are
enriched in membrane proteins from the parent cell such as
integrins, glycoprotein Ib (GPIb), and P-selectin [2]. These
surface markers expressed by MPs are crucial for their
detection in flow cytometry according to their cellular origin
and support the use of patterns of expression of specific sub-
populations of MPs as markers for the onset and progres-
sion of disease.
MPs can also carry membrane receptors and ligands,
in addition to cytosolic proteins such as transcription fac-
tors and enzymes that are functionally bioactive, including
for instance phosphatidylinositol-3-kinase (PI-3K) and
mitogen-activated protein kinase (MAPK) [2]. The identifi-
cation of specific and differentially expressed surface markers
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between MPs derived from healthy and abnormal cells, such
as dysfunctional vascular cells, would provide tools for better
disease diagnosis and progression monitoring.
3.2. Lipid Content of MPs. MPs consist of a lipidic bilayer
membrane identical to the parent cell plasma membrane.
Membranes of MPs compared to cell plasma membranes
have higher flip-flop motions which facilitate the distribution
and exchange of phospholipids between the membrane
leaflets [2, 39]. MP membranes are shown to exhibit a high
content of sphingomyelin and cholesterol which eventually
contributes to their rigidity and resistance to degradation
making them thus ideal carriers for various macromole-
cules including proteins and nucleic acids such as miRNAs
[40, 41]. Macrovesicles can harbor also enzymes implicated
in the metabolism of lipids such as phospholipases A2, C,
and D and carry a variety of bioactive lipids such as free
fatty acids which can modulate cellular responses in recip-
ient cells [42]. The differential lipid composition of MPs
may reflect the conditions of stimulation of the parent cell
and vary according to the content in lipids in the extracel-
lular environment surrounding the emitting cells.
It is anticipated that MPs from subjects suffering from
metabolic disturbances and dyslipidemias may have a spe-
cific lipid and lipid metabolic enzyme composition compared
to MPs from healthy subjects, which may eventually contrib-
ute to a differential effect of these MPs on recipient cells;
however, this hypothesis warrants further investigation. The
numbers of MPs from platelets [43] and those from T cells
or neutrophils and those harboring TF [44] were found to
have a negative correlation with plasma levels of plasma
HDL cholesterol.
3.3. Nucleic Acids andMicroRNA Content of MPs. In addition
to carrying bioactive lipids, membrane, and cytoplasmic pro-
teins and other organelles and nuclear components from the
parent cell, MPs can also carry nucleic acids, specifically
mRNA and microRNA (miRNA), suggesting MPs can
deliver genetic material to recipient cells [5]. MicroRNAs,
which are small noncoding RNAs, play a key role in the epi-
genetic regulation of gene expression and control many met-
abolic and physiological processes associated with health and
disease. Circulating MPs appear to be an efficient carrier for
miRNA and a tool for their transfer to target cells where they
can modify the physiological response of the cell.
It has been reported that platelets carry a rich and diverse
content of more than 400 miRNAs [45, 46]. Importantly, the
miRNA cargo content of platelet-derived MPs differs under
disease conditions and upon cellular activation [47, 48].
The treatment of cells with thrombin, a potent platelet
agonist, altered the miRNA signature of platelets and
platelet-derived MPs with differential expression of miR-15a,
miR-339-3p, miR-365, miR-495, miR-98, and miR-361-3p
being reported [46, 47]. It is now becoming apparent that
diabetes induces its own miRNA signature which may con-
tribute to the onset of diabetes-induced disturbances. The
pattern of expression of 5 plasma miRNAs, miR-15a,
miR28-3p, miR-126, miR-223, and miR-320, was found to
form a unique molecular signature enough to differentiate
between individuals with and without diabetes [49]. Laffont
et al. [47] reported that when platelets were activated with
thrombin release, they selectively and preferentially
released MPs rich in miR-223 [47]. Recently, Jansen et al.
[50] reported in a cohort composed of 80 control subjects
and 55 patients suffering from type-2 diabetes that
endothelial-derived MPs from diabetics had a lower expres-
sion of miR-126 and miR-26a compared to controls. Intra-
cellular miR-126 expression level was reported to define
the regenerative capacity and proangiogenic capacity of
CD34+ peripheral blood mononuclear cells [51] and circu-
lating angiogenic early outgrowth cells [52].
4. Methods of Detection of MPs
Using a variety of methods, it is quite easy to detect MPs in
body fluids. These techniques include assessing the concen-
tration of proteins carried by MPs, flow cytometry analysis
using cell-specific antigen markers, or ELISA assays to detect
the prothrombotic activity of MPs based on the assumption
that all MPs expose PS at their surface and can thus interact
with annexin V. More recently, new single-particle detection
instruments have been used for the analysis of MPs, includ-
ing the resistive pulse sensing (RPS) and the nanoparticle
tracking analysis (NTA), which can measure the size distri-
bution and the concentration of in-solution MPs [53, 54].
Because of the tendency of MPs, especially those of a platelet
origin, to aggregate during the process of isolation by centri-
fugation, single-particle detection instruments (e.g., RPS and
NTA) can detect a lower concentration of MPs. However,
flow cytometers which are particle size-insensitive instru-
ments can detect these large aggregates, and thus, a higher
concentration is detected [53, 54].
Flow cytometry analysis is the most preferred technology
nowadays to trace MPs because of its high speed of detection
and the availability of more sensitive machines. With flow
cytometry, there is a possibility to determine the total num-
ber of MPs as well as the cellular origins of MPs by targeting
specific surface antigens expressed by MP particles from a
specific cell origin. However, owing to the differences
between flow cytometers in terms of their optical configura-
tion and sensitivity of detection and because of the absence
of standard units for the measurement of MPs, the compari-
son of data between laboratories is difficult which hinders the
potential use of MPs as a diagnostic and/or prognostic tool
for diseases due to the variability and nonreproducibility of
results depending on the machine used [53].
The need for standardization of techniques of detection
of MPs by flow cytometry was recognized by the Scientific
Standardization Committee on Vascular Biology (SSCVB)
of the International Society on Thrombosis and Hemostasis
(ISTH), which launched an initiative over 6 years ago to stan-
dardize MP measurements using flow cytometry following a
survey that highlighted that nearly 75% of laboratories use
flow cytometry to count and phenotype MPs according to
cellular origins in clinical samples (e.g., plasma). An inaugu-
ral collaborative workshop was established to determine both
the resolution and the level of background noise of major
flow cytometers used across several research laboratories.
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The other objective of this workshop was to define the repro-
ducibility of platelet-derived MP enumeration in human
plasma between different instruments. The strategy followed
was to use Megamix® fluorescent calibrated beads to allow
for a reproducible setup of MP window analysis [55].
Lacroix et al. [56] tested 49 flow cytometers in 40 labora-
tories and found that the instruments tested had very hetero-
geneous forward scatter (FS)/FS channeling (FSC) resolution
and machine background noise. The authors also reported
that the use of Megamix® helped in identifying and fixing
some of the parameters affecting FS/FSC resolution and that
eventually 33 instruments tested were validated [56]. None-
theless, because of the huge variety of optical designs in flow
cytometers available on the market, it was possible to achieve
an efficient universal standardization methodology to count
platelet-derived MPs. The consortium observed, however,
that the resolution was better and more homogenous in a
subset of instruments using side scatter (SSC) instead of
FSC. Thus, another set of beads was chosen to better respect
the design of SSC-focused flow cytometers [57].
More recently, another workshop was organized by the
SSCVB to test a new strategy for the standardization of MP
detection by flow cytometers and to evaluate interinstrument
reproducibility in detecting platelet-derived MPs. This new
strategy used two different types of beads to suit instruments
of different optical designs (Megamix-Plus® FSC or SSC
beads). The study by Cointe et al. [58] included 44 laborato-
ries across 17 countries and had 52 instruments registered
for testing. Flow cytometers qualified for inclusion in the
strategy of scandalization according to their resolution and
low levels of background noise. All these instruments could
correctly rank levels of platelet-derived MPs in a plasma.
The interlaboratory variance in the enumeration of MPs
was between 28 and 37%. The authors showed that the use
of size-calibrated beads can successfully be utilized to stan-
dardize MP counting across different instruments and labo-
ratories if special care is taken to consider the internal
instrument behavior for size-related measurements and this
independently of using FSC or SSC as the relative sizing
parameter [58]. Despite this second study which only inves-
tigated parameters for the detection of platelet-derived MPs
and only focused on the optimal scatter-based gating of the
MP population, it is a very important initiative and an
important step forward standardizing conditions of detec-
tion of MPs by flow cytometry.
One major challenge in using flow cytometers in detect-
ing MPs is still the limit of the detection, and further techno-
logical developments are thus required to improve the
detection of smaller MPs. Furthermore, additional efforts
from the extracellular vesicle community are still warranted
to improve standardization methods for MP detection for
an optimal use of circulating MPs as routine laboratory diag-
nosis and/or prognosis tools.
5. MPs as Biomarkers of
Cardiovascular Diseases
Increased numbers of plasma MPs were reported in
several cardiovascular diseases associated with insulin
resistance, inflammatory, and/or procoagulant states [5].
In these pathologies, platelet-derived MPs were found to
represent the dominant subpopulation. However, MPs
from other origins including endothelial cells, erythrocytes,
or leukocytes were also found to be increased in certain
pathological states such as metabolic syndrome [16], acute
coronary syndrome [59, 60], severe hypertension [61], and
type-2 diabetes [62]. Two key features of these disease
states are endothelial dysfunction and impaired microcir-
culation with which the levels of circulating MPs fre-
quently correlate indicating that MPs carry cellular
messages that may contribute to the onset and progression
of these pathologies.
Circulating MPs found in the plasma originate from ves-
sel wall cells such as endothelial and smooth muscle cells
and other circulating cells such as platelets, erythrocytes,
and leukocytes. However, most of these MPs are derived
from platelets which represent nearly 80% of the total popu-
lation of circulating MPs. An important physiological role of
platelets is the control of hemostasis by providing a mem-
brane surface to enhance blood coagulation and promote
the generation of the fibrin network in the hemostatic plug
[63]. Platelets have a very high rate of scrambling of mem-
brane lipids and when stimulated generate MPs most rapidly
especially those exposing PS which contributes in preventing
bleeding; however, an excessive shedding of MPs may cause
thrombotic complications [12]. Platelets produce MPs which
display a heightened prothrombin-converting activity and
which provide an extended membrane surface to promote
coagulation. It has been reported that MPs originating from
platelets are 50- to 100-fold more procoagulant than acti-
vated platelets [13]. However, although high circulating
levels of platelet-derived MPs were reported in many dis-
ease conditions, changes in nonplatelet-derived MPs, partic-
ularly those originating from endothelial cells, were found
to contribute a key role in the pathogenesis of these disor-
ders [15–18].
MPs are recognized today as promising biomarkers for
the diagnosis and monitoring of disease progression
because total levels of MPs or those from specific cellular
origins were found to correlate with the severity or the
progression of several disorders. An increase in the num-
bers of MPs from a specific cell population may represent
a signature of injury and a marker of changes to which
these cells are subjected to. For instance, endothelial MP
levels were found to be good predictors for the health of
the endothelium and to correlate with endothelial dysfunc-
tion. For example, high levels of endothelial MPs were
found to correlate positively with arterial erectile dysfunc-
tion in patients with insulin resistance [64] and with endo-
thelial dysfunction in patients suffering from chronic
ischemic left ventricular dysfunction [65]. The circulating
levels of platelet-released MPs were associated with carotid
and intima/media thickness and corporal in mass in obese
subjects [66]. Activated leukocyte-derived MPs (CD62L+)
were found to positively correlate with oxyhemoglobin
desaturation index (ODI) in patients with obstructive sleep
apnea which do not suffer from any cardiovascular comor-
bidities [18].
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6. Circulating MPs in Insulin-Resistant
States and Diabetes
6.1. Impact of Diabetes on MP Expression Profile. Much
evidence shows that circulating numbers of MPs are more
elevated in patients with diabetes and in experimental animal
models of diabetes and they contribute to the development of
cardiovascular complications associated with diabetes. A
meta-analysis study by Li et al. [67] investigated the relation-
ship of MPs with type-2 diabetes. The authors included 48
studies with a total number of 2,460 patients suffering from
type-2 diabetes and 1,880 nondiseased volunteers, of which
34 studies were quantitatively assessed. The general analysis
revealed that type-2 diabetes patients, regardless whether they
had comorbidities or not, exhibited higher circulating levels
of total MPs, platelet-, monocyte-, and endothelium-derived
MPs in comparison to healthy volunteers. However, the
count of leukocyte-derived MPs was similar between controls
and patients [67].
Previously, Sabatier et al. [68] investigated circulating
levels of MPs and determined their procoagulant properties
in both type-1 and 2 diabetics and reported in general all dia-
betics had higher numbers of MPs compared to controls.
However, the authors observed that diabetic patients exhib-
ited a difference in the pattern of expression of MPs accord-
ing to their cell origins and in their prothrombotic action.
Patients with type-1 diabetes had higher levels ofMPs derived
from platelets and endothelial cells in addition to prothrom-
botic MPs compared to controls and type-2 diabetes patients
[68]. Later, Feng et al. [69] reported that type-2 diabetes
patients had elevated levels of procoagulant, platelet, leuko-
cyte, and endothelialMPs compared to controls and endothe-
lial MPs were the only population to positively correlate with
endothelial dysfunction as assessed by flow-mediated dilation
(FMD) in patients [69].
Koga et al. [70] stressed the importance of endothelial
MPs as markers of vascular dysfunction in diabetes and
showed that endothelial MPs were twofold higher in dia-
betics compared to control volunteers and that these MPs
have even higher levels of diabetic patients suffering from
coronary heart disease than those free from such a comorbid-
ity [70]. In another study, Bernard et al. [71] evaluated the
association between plasma levels of endothelial- and
platelet-derived MPs and the presence of coronary noncalci-
fied plaques in patients with diabetes. Researchers reported
that MPs of endothelial origin (CD144+) were highly elevated
in patients exhibiting coronary noncalcified plaque [71]. Tsi-
merman et al. [72] reported that diabetic patients had high
circulating levels of MPs originating from platelets and that
patients also suffering from diabetic foot ulcers had the high-
est numbers of prothrombotic, endothelial, and platelet MPs
compared to patients suffering from diabetes and coronary
heart disease or retinopathy [72].
A study by Zhang and coworkers [73] investigated the
impact of the copresence or not of obesity and type-2
diabetes on the profile of expression of circulating MPs.
The authors reported that regardless of the presence or not
of obesity, type-2 diabetics had high levels of total
platelet-derived MPs or those from activated platelets which
express fibrinogen, tissue factor (TF), or P-selectin. However,
investigators did not find any specific effect of obesity on MP
counts in the absence of type-2 diabetes [73]. The absence of
differences in the presence of obesity alone is contradicting
with previous reports indicating an effect of obesity on the
numbers of circulating MPs [5]. This is potentially due to
the small cohort of patients included in this study (5 to 11
patients per group) [73].
6.2. MP Expression in Type-2 Diabetes and Asymptomatic
Atherosclerosis. Recently, Berezin et al. [74] investigated the
phenotype of expression of circulating MPs between healthy
volunteers and patients with type-2 diabetes either with
angiographic evidence of asymptomatic atherosclerosis or
without any known coronary atherosclerosis. The authors
found that in comparison to controls and diabetics with no
angiographic evidence of atherosclerosis, patients with
asymptomatic atherosclerosis had elevated numbers of circu-
lating platelet-derived (CD41a+) and endothelial-derived
(CD144+/CD31+ or CD144+) MPs in addition to MPs from
procoagulant endothelial cells (CD31+/annexin V+). Using
a multivariate regression model, the authors found that
MPs from procoagulant endothelial cells (CD31+/annexin
V+) were an independent predictor for nonsymptomatic ath-
erosclerosis [74].
6.3. Differential MP Origins and Endothelial Dysfunction in
Obesity. High circulating levels of MPs from different origins
were also observed in various studies of patients with obesity,
which is closely associated with insulin resistance and consid-
ered number one contributor to the development of type-2
diabetes. Several studies in obese children suggested a predic-
tive potential for MPs for future adverse cardiometabolic
events. A cross-sectional study by Bruyndonckx et al. [75]
investigated the relationship betweenmicrovascular endothe-
lial dysfunction and numbers of MPs derived from endothe-
lial cells and endothelial progenitor cells (EPCs) in a cohort
composed of 57 obese and 30 age- and sex-matched and
normal weight children. The noninvasive measurement of
microvascular endothelial function by determining the
peripheral arterial tonometry at the distal phalanx, that
reflects endothelial function at the level of small resistance
arteries, revealed that obese children had significantly
impaired peripheral endothelial function in addition to a
lower number of circulating EPCs and a high level of circulat-
ing endothelial-derived MPs (CD31+/CD42b−) compared to
control children. Single regression and multivariate analysis
showed that the peak response (or the ratio between postoc-
clusion pulse-wave amplitude over the baseline amplitude)
correlated negatively with endothelial-derived MPs but posi-
tively with EPCs count that were both independent determi-
nants of the peak response together with systolic blood
pressure [75].
6.4. MP Expression Profile in Metabolic Syndrome. Obesity is
often associated with other comorbidities including insulin
resistance, type-2 diabetes, dyslipidemias, and hypertension.
This association of cardiometabolic disturbances is com-
monly referred to as the metabolic syndrome (MetS) [76,
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77]. The pathophysiology of MetS is tightly related to insulin
resistance and excess of fatty acids [78, 79] in addition to
low-grade inflammation [77, 79, 80]. The combination of
inflammatory factors with excessive production of reactive
oxygen species (ROS) contributes to the development of car-
diovascular disturbances in MetS [5]. Several studies investi-
gated the count and phenotype of circulating MPs present in
the plasma from patients with MetS. Agouni et al. [16] deter-
mined the count and phenotyped plasma MPs according to
their cellular origins in 43 MetS patients and 37 volunteers.
It was observed that MetS patients had higher numbers
of total MPs in comparison to controls, in addition to pro-
thrombotic MPs (annexin V+) and those originating from
platelets, endothelial cells, and erythrocytes [16]. These
observations were also corroborated by the work of Helal
et al. [81] in a bicentric cohort study of MetS patients.
The authors also found that BMI correlated positively with
the number of prothrombotic and endothelial-derived
MPs [81].
These studies strongly indicate that MPs are potential
biomarkers for the diagnosis, stratification, and follow-up
of disease progression and development of cardiovascular
comorbidities for metabolic disorders where insulin resis-
tance is a central pathophysiological driver such as obesity,
diabetes, and MetS. These findings also highlight the crucial
role that MPs may play in the development of metabolic dis-
eases and in the onset and/or maintenance of cardiovascular
complications associated with these pathological states.
7. Pathophysiological Roles of MPs in Altering
Cell Signaling and Causing Cell Injury in
Insulin-Resistant States and Diabetes
In the last decade, many studies were conducted to investi-
gate the role of MPs as active effectors in the onset and pro-
gression of diabetic cardiovascular complications. Cells
subjected to pathological stimuli have modified intracellular
responses, and thus, MPs generated from these cells can
transfer these deleterious biological messages to recipient
cells to modify in turn their cellular responses.
MPs can transfer biological information to recipient cells
through multiple potential mechanisms although the exact
process is not fully understood yet. These mechanisms of
interaction with target cells may involve the following: (i)
direct interaction between surface proteins in a ligand/recep-
tor type of interaction; (ii) transfer to target cell of surface
receptors, ligands, channels, proteins, genetic material, and
lipids; (iii) merging between membranes of MPs and target
cells; and (iv) internalization of MPs inside the target cell.
The mechanism of interaction with recipient cell involving
ligand and receptor interaction may rapidly either switch
on or switch off intracellular signaling responses; however,
the other means of interaction will involve more complex
changes of cellular responses inside target cells. MPs can also
interact with recipient cells through more than one of these
mechanisms. For instance, it has been previously reported
that MPs carrying the morphogen Shh were able to activate
the morphogen’s signaling pathway to enhance endothelial
angiogenic process and NO release [7, 82]. However, two
hours following this surface interaction, MPs carrying Shh
were internalized by endothelial cells and enhanced the
expression of antioxidant enzymes [83]. Figure 1 summarizes
the mechanisms of interaction of MPs with recipient cells.
In the next section, we will discuss the role of MPs in the
onset and maintenance of cellular dysfunction and injury
associated with insulin resistant states and diabetes with spe-
cial emphasis on the molecular mechanisms involved. The
major alterations in circulating levels of MPs and their
molecular contribution to diabetes-induced complications
in humans and in vivo and ex vivo models are summerized
in Table 2.
7.1. MPs and Vascular Dysfunction. Due to its direct expo-
sure to blood stream, one major target of circulating MPs
are endothelial cells, which play an important role in the
maintenance of vascular homeostasis by achieving a balance
between vasoactive agents (vasodilators and vasoconstric-
tors) and prothrombotic and antithrombotic factors in addi-
tion to a tight control of vascular permeability among other
key actions. Physiological levels of shear stress regulate the
homeostasis of endothelial cells; however, extreme distur-
bances in shear stress due to changes in vascular pressure
can imbalance the release of endothelium-derived factors
leading to endothelial dysfunction.
Endothelial dysfunction is referred to as the reduced
capacity of vessels to dilate in response to the activation of
endothelial cells by humoral or mechanical mediators such
as shear stress or bradykinin. It is now widely recognized that
endothelial dysfunction is an independent predictor of future
adverse cardiovascular events which are widely associated
with obesity and diabetes. Most notably, a decrease of endo-
thelial NO production and bioavailability, a heightened
release of vasoconstrictor mediators, and an enhanced oxida-
tive stress, which altogether lead to alterations of vascular
reactivity, cause vascular inflammation and vascular remod-
eling by affecting the levels of proteins and enzymes involved
in these processes. It is expected that MPs may affect all these
vascular events that contribute to endothelial dysfunction.
MPs produced from activated vascular cells, such as
endothelial cells, are biomarkers of cell injury; however, they
are also capable of interacting with neighboring cells in an
autocrine or paracrine mechanism and modify therefore the
cellular responses of target cells including the emitting cells
themselves. Jenkins et al. [84] reported that disturbed blood
flow in the forearm of healthy men by distal cuff occlusion
was shown to increase endothelial MPs in the experimental
arm by nearly 9-fold after 20 minutes only, while activated
endothelial MPs expressing E-selectin (CD62E+) increased
by 4-fold [84]. Even though arteries in the forearm are less
prone to atherosclerosis, it was possible to observe acute
changes in activated endothelial MPs, suggesting that in
atherosusceptible arteries from the elderly or individuals suf-
fering from comorbidities that are associated with impaired
endogenous endothelial repair mechanisms (e.g., obesity or
type-2 diabetes), the effects might be more severe [84]. The
acute reduction of physical activity for 5 consecutive days
was also reported to increase the numbers of total and
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activated endothelial-derived MPs in healthy volunteers,
which was associated with an impairment in popliteal artery
flow-mediated dilation (FMD) [85]. These studies indicate
that acute changes in MP release not only are early bio-
markers of cell injury but can also be considered active
players and conveyers of biological message which contribute
to changes in the vascular function.
Several studies have reported a relationship between num-
bers of total MPs or specific cell populations and endothelial
dysfunction; however, few studies looked at the molecular
mechanisms underpinning the actions of MPs on endothelial
cells. Ishida et al. [86] found that streptozotocin-injected rats
(amodel of type-1 diabetes) had high numbers of plasmaMPs
originating from platelets (CD61+) and activated platelets
(CD62P+) in addition to procoagulant MPs (annexin V+)
compared to control animals. They also found that the
ex vivo exposure of carotids from control rats to diabetic
MPs reduced endothelium-dependent relaxation by blunting
eNOS protein expression [86]. Using a diet-induced obesity
rat model, Heinrich et al. [87] reported that obese rats had
higher circulating MP levels compared to chow diet-fed ani-
mals, including those of procoagulant, endothelial, platelet,
leukocyte, monocyte, and T lymphocyte origins. The incuba-
tion of endothelial cells in vitro with MPs from obese rats
enhanced the expression of vascular cell adhesion molecule
1 (VCAM-1) and increased oxidative stress indicating that
MPs from insulin resistant animals induced endothelial dys-
function [87].
Previously, Martin et al. [88] observed that MPs engi-
neered in vitro from apoptotic T lymphocytes reduced
endothelium-dependent relaxation and impaired shear-
mediated dilation in mouse aortas and small mesenteric
arteries, respectively. These effects were related to a deceased
expression of eNOS and overexpression of caveloin-1, a neg-
ative regulator of eNOS. Furthermore, the authors found that
MPs derived from diabetic T lymphocytes or circulating total
MPs from diabetic patients blunted eNOS protein expression
in HUVECs [88]. Tesse and coworkers [89] have shown later
that ex vivo exposure of mouse aortic rings to MPs from
either apoptotic T lymphocytes or patients with diabetes
caused impaired vascular response to vasoconstrictor agents.
This effect was linked to an enhanced release of NO and
prostacyclin mediated by NF-κB-induced upregulation of
inducible forms of NOS (iNOS) and cyclooxygenase
(COX-2). The authors also observed that in vivo injection
of mice with MPs derived from apoptotic T lymphocytes
impaired vascular response to vasoconstrictors, which was
prevented by the concomitant administration of both NO
and COX-2 inhibitors [89]. Interestingly, Tesse et al. [89] also
observed that the vascular effects mediated by diabetic and
T lymphocyte-derived MPs involved the interaction of
Fas-ligand (FasL or CD95L) carried out by MPs its receptor
(Fas or CD95) expressed by smooth muscle cells [89].
Agouni et al. [16] observed that MPs collected from
patients suffering from MetS reduced endothelium-
mediated vasodilation in aortas of mice that received an
intravenous injection of MetS MPs in comparison to those
that received MPs from MetS-free subjects. Of interest, the
authors found that in spite the majority of MPs from MetS
patients originated from platelets, the effects mediated by
MetS MPs on endothelial function were mainly caused by
MPs of nonplatelet origin [16]. The same group has subse-
quently found thatMetSMPs could also interact with smooth
muscle cells to cause vascular dysfunction [15]. The team
Plasma membrane
Membrane
budding
Activated/apoptotic
secreting cell
Cell
signaling
Release of
biological
content
Recipient cell
MP
a. Ligand-receptor interaction
b. Protein transfer
c. Direct fusion
d. Endocytosis
Figure 1: Mechanisms of interaction of MPs with recipient cells. MPs are first released from activated or apoptotic cells by direct budding of
the plasma membrane. MPs can then directly interact with the target cell via ligand-receptor interaction which results in cell signaling (a),
transfer proteins (i.e., adhesion molecules, MHC, and membrane receptors) from the MP vesicle to the surface of the target cell (b), or
deliver the biological content of the MP to the target cell through either direct fusion of the MP with the plasma membrane of the target
cell (c) or endocytosis (d). PS: phosphatidylserine, MHC: major histocompatibility complex, MP: microparticle.
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found that MetS MPs injected into healthy mice impaired
vasocontractile response in the aorta by stimulating an
inflammatory response in the vessel through the overexpres-
sion of iNOS increasing thus vascular NO production [15].
More recently, Safiedeen et al. [90] have reported that
MPs engineered in vitro from apoptotic T lymphocytes or
obtained from MetS patients activated the proinflammatory
signaling pathway of endoplasmic reticulum (ER) stress, in
cultured human aortic endothelial cells (HAECs) and
in vivo in mouse aortas, which contributed to MP-induced
endothelial dysfunction [90]. Protein synthesis and key post-
translational modifications occur inside the ER. In situations
associated with an increased demand on protein synthesis
such as obesity or diabetes, there is an overload on the ER
leading to the accumulation of misfolded and/or unfolded
proteins within the ER lumen that results in the activation
of the unfolded protein response (UPR) with the primary
goal to improve ER homeostasis and clear the protein load
that has accumulated to improve cell viability and survival
[91, 92]. However, when the activation of the UPR pathway
prolongs and becomes chronically switched on, this can lead
to a situation of “ER stress,” which is associated with the
activation of adverse cellular responses that may lead to cell
death [91, 92]. Several reports linked ER stress response
activation to the onset of insulin resistance in obesity and
diabetes [93, 94]. ER stress is also tightly associated with
the activation of major inflammatory intracellular signaling
response such as nuclear factor (NF)-κB and c-Jun
N-terminal kinase (JNK). The extreme activation of ER
stress may cause apoptosis [91, 92, 95, 96].
Endothelial cells undergoing apoptosis are dysfunctional,
more procoagulant, and prone to adhere to platelets [97]. ER
stress-mediated apoptosis involves, at least, three apoptotic
subpathways: the first is through the activation of proapopto-
tic transcription factor C/EBP homologous protein (CHOP),
the second is controlled by the activation of JNK signaling
response, and the third is due to the activation of
ER-associated caspases 3 and 12 (only found in rodents)
[92, 95, 96]. ER stress response was shown to be activated
in endothelial cells lining vascular areas with the highest sus-
ceptibility to develop atherosclerotic plaques and hence indi-
cate an involvement of this pathway in the development of
endothelial dysfunction [98].
Recently, it has been shown that high glucose disturbed
NO signaling and impaired angiogenic capacity of cultured
HUVECs through the activation of ER stress response [99].
Interestingly, Safiedeen et al. [90] reported that the exposure
of HAECs to MetS or apoptotic T lymphocyte-derived MPs
caused the activation of serval key ER stress markers, includ-
ing the nuclear translocation of activating transcription fac-
tor (ATF)-6, and reduced endothelial NO production [90].
All these effects were interestingly prevented by the pretreat-
ment of cells with a chemical chaperone, tauroursodeoxy-
cholic acid (TUDCA), to improve the native functions of
the ER and improve protein folding [90]. The intravenous
injection of MetS or apoptotic T lymphocyte-derived MPs
into mice impaired endothelium-mediated vasodilation in
the aorta; however, the preinjection of animals with TUDCA
prevented this deleterious effect on vascular function. The
authors also found that the effects of MetS and apoptotic T
lymphocyte-derived MPs on the activation of ER stress in
HAECs involved two membrane receptor interactions, Fas/-
FasL and low-density lipoprotein receptor (LDL-R), that
were both been previously found to be implicated in the vas-
cular effects of MetS or apoptotic T lymphocytes-derived
MPs [15, 89, 100]. Furthermore, MetS and apoptotic T
lymphocyte-derived MPs increased the protein expression
of the neutral sphingomyelinase (SMase) that was found to
contribute to the activation of ER stress response [101]. The
neutralization of FasL expressed at the surface of MPs or
the blockade of the LDL-R expressed at the surface of endo-
thelial cells normalized the levels of protein of expression of
SMase. Furthermore, the blockade of SMase action reversed
the actions of MPs on NO signaling and ER stress response
activation, suggesting that the effects of MPs are mediated
through neutral SMase [90].
Altogether, these studies highlight the complex interac-
tions of MPs from insulin resistant or diabetic patients
with cells of the vessel wall to induce vascular dysfunction
which eventually contributes to the development of
comorbidities associated with these metabolic disorders.
The deeper understanding of the molecular mechanisms
involved will pave the way for the identification of novel
therapeutic targets to reduce the burden of these cardio-
metabolic disturbances on the quality of patients’ lives.
7.2. MPs and Ischemic Diseases. MPs are potential vectors of
biological messages between cells and were found to play
key roles in regulating angiogenesis in ischemic conditions.
Numerous studies have demonstrated that human T
lymphocyte-derived MPs carrying the morphogen Shh were
able to regulate the proangiogenic activity of endothelial
cells in vitro through the regulation of the expression of
proangiogenic genes [82, 83]. Importantly, the proangio-
genic effects of these MPs were further confirmed in vivo
using mouse models of hindlimb ischemia. The authors
found that the treatment of the ischemic mouse with MPs
bearing Shh enhanced the postischemic reparative neovas-
cularization by regulating NO pathway and modulating
angiogenesis-related gene expression in these models [102].
In another study using an in vivo mouse model of angiogen-
esis, Benameur et al. [103] observed that MPs carrying per-
oxisome proliferator-activated receptor (PPAR)-α play a
stimulatory role on neovascularization mediated by EPCs
originating from the bone marrow. The MP-induced angio-
genic effects were essentially mediated by the improvement
of EPC differentiation and the enhancement of the proan-
giogenic activity of endothelial cells [103].
Diabetes is associated with a high risk of ischemic dis-
eases and other associated complications as discussed in this
review. Given the increasing clinical significance of MPs in
various pathologies and their important biological functions
as well as the importance of other cell-derived molecular
partners, a growing number of studies have started investi-
gating the contribution of MP-derived miRNA transfer in
modulating the pathogenesis of many diseases. MPs harbor-
ing miRNA have been reported in multiple diseases including
cancer and cardiovascular disorders [104]. It was observed
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that the expression of endothelial-specific miRNA molecules
inMPs shed from endothelial cells was significantly altered in
diabetes mellitus with stable coronary artery diseases. In
addition, endothelial-derived MPs bearing miR-126 were
shown to promote vascular endothelial repair through the
transfer of miRNA to the target cells. This effect was abol-
ished under hyperglycemic conditions [105]. In another
translational approach, it was further confirmed that diabetes
mellitus correlated with impaired expression of not only
endothelial miR-126 but also miR-26 in circulating MPs
when compared to patients without diabetes mellitus. These
results underscore the potential implication of endothelial-
derived MPs in modulating vascular biology and conse-
quently leading to diabetes mellitus vasculopathy [50].
Altogether, these findings support that diabetics with lower
levels of miR-126 and miR-26 can be at a higher risk of
concomitant coronary artery disease.
Consistent with previous findings published by Caporali
et al. [106], a more recent research has provided a new level
of understanding of the contribution of MPs to the develop-
ment of diabetes-mediated vascular complications, with par-
ticular emphasis on the interaction between endothelial cells
and pericytes in a rodent model of hindlimb ischemia.
Results demonstrated that MPs secreted from diabetic endo-
thelial cells and carrying miR-503 were subsequently deliv-
ered to neighboring pericytes to modify the permeability of
vessels and alter the postischemic angiogenic process in limb
muscles via the regulation of genes under the control of
miR-503, such as VEGFA and EFNB2 (Ephrin B2) [107].
It has also been observed that db/db mice, a genetic
rodent model of type-2 diabetes, exhibited elevated plasma
MPs originating from endothelial cells compared to
wild-type mice and that these MPs caused a reduction in
cerebral microvascular density [108]. The authors found that
MPs collected from db/db animals also impaired the proper-
ties of EPCs as evidenced by the failure of EPCs (obtained
from control mice) prestimulated with MPs collected from
db/db to improve ischemic damage following their adminis-
tration into diabetic mice [108].
Because of the importance of tissue factor (TF) in regulat-
ing angiogenesis, the crucial role of MPs derived from micro-
vascular endothelium that bear TF was demonstrated in
enhancing collateral flow and capillary formation in a murine
hindlimb ischemia model [109, 110]. TF-bearing microvas-
cular endothelial-derived MPs accelerated the angiogenic
process through a paracrine control of adjacent endothelial
cells, via a mechanism implicating the β1-integrin pathway,
Rac1-ERK1/2-ETS1 to form new and functional mature ves-
sels. Furthermore, Edrissi et al. [111] reported that MPs shed
during cerebral ischemia enhanced the permeability of endo-
thelial cell layer. This increase in endothelial permeability
was, at least, mediated by an accelerated apoptosis induced
by the transfer of the activated TNFα pathway molecules,
caspase 3, and Rho kinase delivered by MPs to the target cells
[111]. Tsimerman et al. [72] also observed that MPs obtained
from patients suffering from diabetes enhanced the procoa-
gulant activity of endothelial cells. The prothrombotic activ-
ity was the highest in endothelial cells stimulated by MPs
collected from diabetic patients with severe diabetic foot
ulcers, suggesting a role for these MPs in thrombotic compli-
cations associated with diabetes [72].
These findings open up intriguing new therapeutic strat-
egies based on the use of MPs as potential novel therapeutic
tools in the treatment of critical limb ischemia and other
ischemic diseases. Taking into account the different proper-
ties of MPs, much evidence supports the concept of expand-
ing the MPs’ use as efficient therapeutic tools in altered
angiogenesis associated with ischemic diseases [112].
7.3. MPs and Myocardial Infarction.Diabetic patients are at a
high risk of developing acute coronary syndromes (ACS).
Due to their procoagulant and proinflammatory potential,
MPs were found to contribute to the formation of thrombus
and the progression of atherosclerotic disease. High circulat-
ing levels of MPs have been observed in ACS [113, 114]. ACS
include unstable angina, non-ST segment elevation myocar-
dial infarction (NSTEMI), and ST-segment elevation myo-
cardial infarction (STEMI) in addition to sudden death.
ACS are frequently characterized by the buildup of vulnera-
ble atherosclerotic plaques in coronary arteries and manifest
following the plaque rupture and the occlusion of arteries by
the formed thrombi [115].
Several studies reported high circulating levels of MPs
from various cell origins in STEMI patients and found that
their levels reflected systemic inflammation and cell injury
and activation in addition to correlating with the size of
ischemic cardiac tissue [116–120]. For instance, Porto et al.
[116] observed that STEMI patients had higher levels of
platelet- and endothelial-derived MPs in intracoronary blood
compared to aortic blood and that these MPs correlated pos-
itively with thrombus scores [116]. Furthermore, it has been
reported that the numbers of circulating MPs continued to
increase in the short term following appropriate intervention
in STEMI patients. Zhou et al. [117] followed up circulating
levels of MPs over time in STEMI patients undergoing percu-
taneous transluminal coronary intervention (PCI) (before
and up to 48h after PCI). The authors found that platelet
MPs increased directly after the PCI and continued to rise
over time until the end of follow-up period, whereas the
levels of leukocyte- and endothelial-derived MPs decreased
after the PCI, but rose thereafter until the end of the
follow-up period [117].
Recently, Chiva-Blanch et al. [118] compared the profile
of MP expression between STEMI and NSTEMI patients.
The authors found that STEMI patients had higher numbers
of platelet-derived MPs compared to NSTEMI in spite of
receiving a dual antiplatelet treatment, indicating that the
process of platelet activation may be more implicated in the
pathogenesis of STEMI. STEMI patients exhibited a higher
plasma TF procoagulant activity compared to NSTEMI
patients, which positively correlated with the number of
MPs originating from platelets, monocytes, and those har-
boring TF [118].
However, MPs are not always playing a deleterious role in
cardiac ischemic disease. The process of remote ischemic
conditioning (RIC) is a good example for this. RIC consists
of subjecting a remote area of heart muscle to brief reversible
cycles of ischemia and reperfusion, conferring a general
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protection to distant tissues and organs, which become resis-
tant to injury caused by prolonged episodes of ischemia and
reperfusion [121]. Despite the fact that effector pathways of
RIC were described in the literature, the propagation patterns
of cardioprotective signals between organs remain unclear
[122]. Interestingly, it was shown that the release of MPs
from the heart increased following a preconditioning proce-
dure and these MPs were found to contribute to the forward-
ing of protective remote conditioning signals. This suggests
that MPs exert a protective effect in ischemic heart diseases
[123]. Very recently, Bueno-Betí et al. [33] reported that
MPs engineered in vitro and harboring the morphogen Shh
restored the vasculogenic properties of EPCs obtained from
patients suffering from myocardial infarction to the levels
of healthy volunteers [33].
7.4. MPs and Ischemic Stroke. Diabetes mellitus is recognized
as an important risk factor for stroke and is associated with
increased incidence of ischemic stroke at all ages [124, 125];
however, the chronic influence of stroke on cell activation
and dysfunction processes remains poorly understood. Cir-
culating levels of neural precursor cell (NCP)-derived MPs
(CD56+/CD34+/annexin V+) were found to be higher in
stroke patients in comparison to high cardiovascular risk
controls. This increase was chronically maintained when
compared to the levels measured at the onset of attacks in
patients with lower lesion volumes. However, a decreased
level of NCP-derived MPs and increased levels of smooth
muscle cell-derived MPs were observed in patients with
higher volume of cerebral lesions. These data suggest that
NCP-derived MPs can reflect an ongoing repair of the dam-
aged brain tissue in patients and can be considered as a
potential biomarker of stroke.
The specific underlying pathophysiological mechanisms
of the involvement of MPs in stroke need further investiga-
tions [126]. MPs harboring TF (TF+-MPs) are produced in
various pathological conditions including atherosclerosis,
cancer, acute coronary syndrome, and diabetes where they
can trigger thrombosis cascade [127]. It is well documented
that the presence of TF onMPsmarkedly increased their pro-
coagulant activity [128]. In a study of acute ischemic stroke,
26% of stroke patients had diabetes; the authors reported sig-
nificantly higher plasma numbers of TF+-MPs and an ele-
vated circulating concentration of TF pathway inhibitor
(TFPI) in stroke patients compared to healthy controls.
Moreover, one week following diagnosis, the activity of
MPs was more elevated in stroke patients not treated with a
tissue plasminogen activator (Alteplase) compared to their
activity at the stroke attacks onset [129].
7.5. MPs and Diabetic Cardiomyopathy. Understanding of
the underlying pathogenic mechanisms of diabetic cardio-
myopathy is necessary for the early detection and control of
this major cardiovascular complication of diabetes [130]. At
early stages, diabetic cardiomyopathy is often unrecognized
due to the lack of pathognomonic features. Indeed, these
early stages are most often nonsymptomatic and only molec-
ular and cellular alterations are taking place. Moreover, the
insignificant alteration in the myocardial structure and
function make the subclinical detection of diabetic cardiomy-
opathy extremely challenging in clinical practice. In addition,
the subclinical state of the disease becomes more critical after
an episode of ischemia. This will reduce the possibility to
restore the heart function to normal level.
Interestingly, previous investigations provided evidence
that miRNAs were found in human biofluids and considered
as a novel potential category of biomarkers for type-2 diabe-
tes [131] and suggested utilization of miRNA as promising
biomarkers for the early diagnosis of subclinical diabetic car-
diomyopathy [132, 133]. Promising preclinical studies sug-
gested that the concept of miRNA and their specific
antagonists could contribute to a better therapeutic control
of heart failure to dyslipidemia, for example, in spite of the
specificity and targeting challenges [134]. The potential of
MP-contained miRNAs as a prominent biomarker for
type-2 diabetes can be implicitly understood from the key
roles that miRNAs play in the control of metabolic and car-
diovascular pathophysiological processes [135].
The early detection of subclinical cardiomyopathy in
diabetic patients using extracellular vesicles as biomarkers
could be a future alternative of antidiabetic treatment. This
can also serve as an early predictor of the diabetic myocar-
diopathy in patients with a high risk of diabetes-associated
complications. Altogether, these new research streams high-
light the crucial and emerging role of extracellular vesicles
and their cargo in understanding cardiovascular physiology
and the pathogenesis of cardiovascular disease associated
with diabetes.
7.6. MPs and Diabetic Retinopathy. Diabetic retinopathy is
another major, but common, complication of diabetes, which
affects the microvasculature. It is an important contributor to
vision loss and blindness in diabetic patients. Small vessels in
the eye have pericytes that control the capillary tone, generate
new capillaries, and protect the vessels against noxious mol-
ecules. Uncontrolled diabetes leads to the loss of pericytes
and degradation of the blood retinal barrier which results
in increased permeability and proliferation of endothelial
cells [136].
Because of the association of diabetic retinopathy with
progressive retinal capillary activation and proliferation, ele-
vated vitreous levels of MPs from different cellular lineages
were detected in patients with proliferative diabetic retinop-
athy. These MPs were especially of platelet, endothelial, and
retinal origins. These MPs were able to stimulate cell migra-
tion and initiation of vessel formation, the key features of
angiogeneis, in an in vivo Matrigel plug assay [137]. The
levels of endothelial- and platelet-derived MPs were dramat-
ically decreased in the vitreous body following a panretinal
laser photocoagulation and after intravitreal treatment
directed against vascular endothelial growth factor (VEGF),
respectively [137]. These findings demonstrate to what
extent MPs participate in the progression of proliferative
diabetic retinopathy and highlight the role of MPs as indica-
tors of therapy effectiveness and as efficient specific bio-
markers for early diagnosis of retinal disturbances.
Different MP populations can exert different effects on
the pathological neovascularization seen in diabetic
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retinopathy. For example, Tahiri et al. [138] have shown that
lymphocyte-derived MPs (LMPs) suppressed laser-induced
choroidal neovascularization (CNV). Given the fact that
macrophages carry proangiogenic properties in CNV, LMPs
were able to modulate the angiogenic properties of macro-
phages, suggesting that LMPs can be considered potent ther-
apeutic antiangiogenic factors in pathological choroidal
neovascularization [138]. Furthermore, extracellular vesicles
released from mesenchymal stem cells that were treated with
high glucose increased angiogenesis and retinal neovascular-
ization in vitro by promoting the dissociation of pericytes
from adjacent endothelial cells which results in uncontrolled
proliferation of endothelial cells, contributing thus to prolif-
erative diabetic retinopathy [139].
7.7. MPs and Diabetic Nephropathy. Diabetic nephropathy is
characterized by the loss of renal podocytes. Podocytes are
crucial for maintaining the proper permeability of the glo-
merular filtration barrier. Upon podocyte injury and loss,
the glomerular filtration barrier’s permeability is increased
which results in the permeation of proteins such as albumin
to the urine, a clinical manifestation of diabetic nephropathy.
Since the loss of podocytes is irreversible, there is a need for a
marker that can detect early cellular injury to podocytes
which will allow for early intervention before clinical mani-
festation of symptoms. Burger et al. [140] indicated that
podocytes can shed MPs into urine and that these MPs are
significantly elevated in diabetic nephropathy in in vitro
and in vivo models, even before the presence of albuminuria
[140]. Similarly, Lytvyn et al. [141] found that patients with
uncomplicated type-1 diabetes had significantly elevated
numbers of podocyte-derived MPs in comparison to
healthy volunteers [141]. It is clear that shedding of MPs
from podocytes happens before the onset of diabetic
nephropathy which supports their use as a diagnostic
marker of renal injury.
Diabetic nephropathy is also an important risk factor for
cardiovascular complications in diabetic patients. Endothe-
lial dysfunction is believed to develop at the early stages of
diabetic nephropathy and cardiovascular disorders. Accumu-
lating evidence is demonstrating that certain MP populations
that are significantly correlated with impaired vascular func-
tion are elevated in chromic kidney disease (CKD) and
end-stage renal failure patients such as MPs from platelets
and endothelial cells [142–144]. Endothelial MPs (CD144+
and CD31+/CD41-) strongly correlated with impaired vascu-
lar function in vivo and impaired relaxation in aortic rings in
response to acetylcholine in vitro [143]. Lu et al. [142] also
found that platelet and endothelial MPs positively correlated
with markers of endothelial injury and platelet activation
(von Willebrand factor and p-selectin, respectively) in
patients with CKD [142]. Previously, Dursun et al. [145]
studied the association between endothelial MPs (CD144+),
arterial stiffness, and atherosclerosis in children suffering
from CKD. The authors reported that the numbers of plasma
endothelial MPs were higher in dialysis patients in com-
parison to predialysis patients and healthy volunteers. Fur-
thermore, it was found that endothelial MPs positively
correlated with blood pressure, C-reactive protein (CRP),
parathyroid hormone, and disease duration, while they cor-
related negatively with glomerular filtration rate (GFR) and
albumin levels [145]. Therefore, we can understand that
MPs are active players in endothelial dysfunction that can
later progress to cardiovascular complications and are not
only biomarkers of endothelial cell activation and injury.
MPs themselves can be used to monitor response to
treatments. The antidiabetic agent teneligliptin and the
lipid-lowering agent simvastatin were tested for their effect
in protecting against endothelial dysfunction in patients with
diabetic nephropathy to prevent the progression to cardio-
vascular disease seen in this population of patients. Since
MPs are markers of and contributors to endothelial dysfunc-
tion, as discussed earlier, they were measured to monitor the
protective effects of these medications. Teneligliptin strongly
reduced the levels of plasma platelet-derived MPs and the
plasminogen activator inhibitor, a hallmark of platelet activa-
tion, in diabetic patients receiving hemodialysis suggesting its
protective effects in this population [146]. Likewise, the treat-
ment of diabetic patients suffering from CKD with simva-
statin resulted in a significant reduction of procoagulant
MPs (PS positive), platelet MPs, and monocyte MPs, suggest-
ing its beneficial effect in ameliorating endothelial dysfunc-
tion [147].
Altogether, MPs can serve as a diagnostic marker because
they are noninvasive, predict early pathological changes in
the endothelium, and can predict the risk of other diabetic
complications. MPs can also be used for monitoring treat-
ment effects. Finally, therapeutic agents can be developed to
target MPs as they appear to have a role in the pathophysiol-
ogy of diabetic nephropathy and other complications.
8. Future Directions
Multiple clinical and preclinical investigations assessed the
impact of treatments of diabetes and its complications on
plasma levels of MPs. Esposito et al. [148] evaluated the
actions of two oral antidiabetics, pioglitazone and metfor-
min, on the numbers of plasma MPs originating from endo-
thelial cells and EPCs in newly diagnosed type-2 diabetes
patients. This study found that following 24 weeks of treat-
ment with pioglitazone, patients’ plasma exhibited a decrease
in endothelial MPs while the numbers of EPC-shed MPs
increased [148]. Furthermore, type-2 diabetes patients who
received miglitol, an oral antidiabetic drug, for a period of 4
months, had lower levels of MPs of platelet origin compared
to controls [149]. Shimazu et al. [150] reported earlier that
another orally available antidiabetic treatment, acarbose, also
reduced circulating numbers of platelet-shed MPs in type-2
diabetes patients [150]. Similarly, teneligliptin, a dipeptidyl
peptidase-4 (DPP-4) inhibitor, significantly reduced plasma
levels of platelet-shed MPs and plasminogen activator inhib-
itor in type-2 diabetes patients receiving hemodialysis [146].
The use of statins was also reported to affect the circulating
levels of MPs patients with diabetes. Almquist et al. reported
that simvastatin significantly reduced total PS-positive MPs,
platelet-derived MPs, and monocyte-derived MPs in patients
with diabetes and CKD [147].
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Approaches to manage body weight were also observed
to modify circulating levels of MPs from select cellular ori-
gins. Morel et al. [151] reported that a very low-calorie diet
for 90 days caused a reduction in body weight in obese
women and lowered plasma levels of MPs from different
origins including procoagulant, leukocyte, and lymphocyte
MPs. Furthermore, the diet improved several cardiac and
metabolic vitals such as leptin levels and blood pressure
[151]. Moreover, endothelial-derived MP levels were found
to be reduced following a high-intensity exercise in over-
weight inactive participants [152].
Treatments based on the use of natural nanoparticles
were also found to be effective in reducing the number of
plasma MPs. For instance, Garavelo et al. [153] reported
recently that the treatment of a rabbit model of atherosclero-
sis, fed a high-cholesterol diet, with natural nanoparticles
obtained from medicinal plants (PTC) combined with
trans-Sialidase (TS) for 6 weeks, reduced the number of total
MPs in addition to those positive for Mycoplasma pneumo-
niae and oxidized LDL. Furthermore, the treatment of ani-
mals with PTC and TS reduced atherosclerotic plaque area
and caused a positive remodeling of ascending aortic seg-
ment [153]. These findings highlight the potential of
nanoparticle-based therapies in modulating the circulating
levels of MPs.
Since MPs are implicated in the onset and progression of
cardiovascular pathologies and diabetes-induced complica-
tions, they can be targeted therapeutically by many strategies.
One strategy is controlling their release to reduce their levels;
however, currently, there is a need to understand the mecha-
nisms involved in the production and shedding of MPs to
better and specifically target them. Another strategy could
be the inhibition of their uptake by modulating specific sur-
face lipids of MPs to prevent deleterious messages from
reaching the recipient cells or inhibiting MP’s surface ligands
that interact with cell surface receptors, in order to prevent
cell signaling. Finally, the modulation of the cargo content
of the MPs to control the biological messages that they carry
can be another strategy.
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